- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07488832
Perfusion intraveineuse de lidocaïne dans la chirurgie de fusion lombaire
Effet de la perfusion intraveineuse peropératoire de lidocaïne sur la consommation postopératoire d'opioïdes et la récupération après une chirurgie de fusion lombaire : un essai contrôlé randomisé
Elective lumbar fusion surgery is associated with moderate to severe postoperative pain and often requires substantial perioperative opioid administration. Excessive opioid use may lead to adverse effects such as nausea, vomiting, sedation, respiratory depression, and delayed mobilization. Intravenous lidocaine infusion has been proposed as part of multimodal analgesia because of its analgesic, antihyperalgesic, and anti-inflammatory properties.
This randomized, placebo-controlled clinical trial aims to evaluate the effect of intraoperative intravenous lidocaine infusion on postoperative opioid consumption and early recovery outcomes in patients undergoing elective lumbar fusion surgery. Patients will be randomly assigned to receive either intravenous lidocaine infusion or placebo during surgery.
The primary outcome is cumulative postoperative opioid consumption within the first 24 hours after surgery. Secondary outcomes include intraoperative opioid consumption, postoperative pain scores, time to first rescue analgesic, quality of recovery, postoperative nausea and vomiting, time to mobilization, and length of hospital stay. In addition, inflammatory and oxidative stress biomarkers including interleukin-6 (IL-6) and markers of thiol-disulfide homeostasis will be measured preoperatively and postoperatively.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Lumbar fusion surgery is frequently associated with significant postoperative pain and often requires high doses of opioid analgesics during the perioperative period. Opioid administration may lead to several adverse effects including postoperative nausea and vomiting, sedation, respiratory depression, and delayed recovery. Therefore, multimodal analgesia strategies are increasingly used to improve postoperative pain control and reduce opioid requirements.
Intravenous lidocaine infusion has gained attention as an adjunct component of multimodal analgesia because of its analgesic, antihyperalgesic, and anti-inflammatory properties. Previous clinical studies have suggested that perioperative systemic lidocaine may reduce postoperative pain intensity, decrease opioid consumption, and improve recovery after surgery. However, evidence regarding its effectiveness in patients undergoing lumbar fusion surgery remains limited.
This prospective, randomized, placebo-controlled study will include adult patients aged 18 years or older with American Society of Anesthesiologists (ASA) physical status I-III who are scheduled for elective lumbar fusion surgery. Participants will be randomly allocated into two groups. Patients in the lidocaine group will receive an intravenous lidocaine bolus followed by continuous lidocaine infusion during surgery, whereas patients in the control group will receive an equivalent volume of normal saline infusion. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery.
All patients will receive standardized general anesthesia and postoperative multimodal analgesia. Postoperative pain will be assessed using the Numerical Rating Scale (NRS). Rescue analgesia will be administered when clinically indicated.
The primary outcome is cumulative postoperative opioid consumption within the first 24 hours after surgery. Secondary outcomes include intraoperative opioid consumption, postoperative pain scores at predefined time points, time to first rescue analgesic requirement, postoperative nausea and vomiting incidence, quality of recovery measured by QoR-15, post-anesthesia care unit length of stay, time to mobilization, and hospital length of stay.
In addition, inflammatory and oxidative stress responses associated with surgery and lidocaine administration will be evaluated. Blood samples will be collected preoperatively and at 6 and 24 hours postoperatively to measure interleukin-6 (IL-6) levels and markers of thiol-disulfide homeostasis.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ankara Bilkent City Hospital
- Numéro de téléphone: +90 312 552 6000
- E-mail: ankarasehir@saglik.gov.tr
Lieux d'étude
-
-
-
Ankara, Turquie (Türkiye)
- Recrutement
- Ankara Bilkent City Hospital
-
Contact:
- Gokhan Erdem, MD, PhD
- Numéro de téléphone: 05326258766
- E-mail: drgokhanerdem@gmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age ≥18 years
- Scheduled for elective lumbar fusion surgery under general anesthesia
- American Society of Anesthesiologists (ASA) physical status I-III
- Ability to provide written informed consent
Exclusion Criteria:
- Refusal to participate in the study
- ASA physical status ≥IV
- Body mass index >35 kg/m²
- Known allergy or hypersensitivity to lidocaine or study medications
- Severe cardiac, hepatic, or renal disease
- Pregnancy
- Neurological disorders affecting pain assessment
- Chronic opioid use
- Use of opioids or antiemetic drugs before surgery
- Inability to cooperate with postoperative assessments
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Lidocaine Infusion
Patients in this group will receive continuous intravenous lidocaine infusion at a rate of 2 mg/kg/h throughout the surgical procedure following induction of general anesthesia. The infusion will be discontinued at the end of surgery. All patients will receive standardized general anesthesia and postoperative multimodal analgesia. |
Continuous intravenous lidocaine infusion will be administered during lumbar fusion surgery at a rate of 2 mg/kg/h following induction of general anesthesia. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery. |
|
Comparateur placebo: Placebo (Normal Saline)
Patients in this group will receive an intravenous infusion of normal saline at an equivalent rate throughout the surgical procedure following induction of general anesthesia. The infusion will be discontinued at the end of surgery. All patients will receive standardized general anesthesia and postoperative multimodal analgesia. |
An intravenous infusion of normal saline (0.9% sodium chloride) will be administered at an equivalent rate during surgery following induction of general anesthesia. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Cumulative postoperative opioid consumption within the first 24 hours after surgery
Délai: 0 to 24 hours after surgery
|
Cumulative opioid consumption during the first 24 postoperative hours will be evaluated. Rescue analgesia will be administered as intravenous tramadol (100 mg) when the Numerical Rating Scale (NRS) pain score is ≥4. The cumulative tramadol dose administered during this period will be recorded in milligrams (mg). |
0 to 24 hours after surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Intraoperative remifentanil consumption
Délai: From induction of anesthesia to the end of surgery
|
Cumulative remifentanil consumption during surgery will be recorded in micrograms (µg). |
From induction of anesthesia to the end of surgery
|
|
Postoperative pain intensity
Délai: At arrival in the post-anesthesia care unit and at 2, 4, 6, 12, and 24 hours after surgery
|
Postoperative pain intensity will be assessed using the Numerical Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain). |
At arrival in the post-anesthesia care unit and at 2, 4, 6, 12, and 24 hours after surgery
|
|
Time to first rescue analgesic requirement
Délai: Within the first 24 hours after surgery
|
Time from the end of surgery to the first administration of rescue intravenous tramadol will be recorded. |
Within the first 24 hours after surgery
|
|
Quality of recovery
Délai: Preoperative baseline and 24 hours after surgery
|
Quality of recovery will be evaluated using the Quality of Recovery-15 (QoR-15) questionnaire, a validated patient-reported outcome measure assessing postoperative recovery. The total score ranges from 0 to 150, with higher scores indicating better postoperative recovery. |
Preoperative baseline and 24 hours after surgery
|
|
Postoperative nausea and vomiting incidence
Délai: 0-24 hours after surgery
|
The incidence of postoperative nausea and/or vomiting and the requirement for rescue antiemetic treatment will be recorded. |
0-24 hours after surgery
|
|
Post-anesthesia care unit length of stay
Délai: Immediate postoperative period (up to 24 hours after surgery)
|
Duration of stay in the post-anesthesia care unit will be recorded in minutes. |
Immediate postoperative period (up to 24 hours after surgery)
|
|
Time to mobilization
Délai: Up to 24 hours after surgery
|
Time from the end of surgery to the first mobilization will be recorded. |
Up to 24 hours after surgery
|
|
Serum interleukin-6 (IL-6) levels
Délai: Preoperatively and at 6 and 24 hours after surgery
|
Serum interleukin-6 (IL-6) levels will be measured to evaluate the inflammatory response. |
Preoperatively and at 6 and 24 hours after surgery
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Thiol-disulfide homeostasis parameters
Délai: Preoperatively and at 6 and 24 hours after surgery
|
Native thiol, total thiol, and disulfide levels will be measured to evaluate oxidative stress and thiol-disulfide homeostasis. |
Preoperatively and at 6 and 24 hours after surgery
|
|
Length of hospital stay
Délai: Through hospital discharge, an average of 5 days
|
Total duration of hospitalization will be recorded in days. |
Through hospital discharge, an average of 5 days
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Gokhan Erdem, MD, PhD, Department of Anesthesiology and Reanimation, Ankara Bilkent City Hospital, Ankara, Turkey
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- La douleur
- Manifestations neurologiques
- Complications postopératoires
- Processus pathologiques
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Douleur, Postopératoire
- Produits chimiques organiques
- Préparations pharmaceutiques
- Anilides
- Amides
- Composés aniline
- Amines
- Acétanilides
- Solutions cristalloïdes
- Solutions isotoniques
- Solutions
- Lidocaïne
- Solution saline
Autres numéros d'identification d'étude
- LidocaineInfusion
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
No plan to share individual participant data.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .